Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03033680 · ClinicalTrials.gov registry record · Phase 1
Establishing 18F-PBR06 PET Imaging as a Viable Pharmacodynamic Endpoint in MSA
A Phase 1 study, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
NCT03033680 is a Phase 1 study that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 17 participants.
The verdict
NCT03033680, a Phase 1 study, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
The specific aims of the study are: Primary: To determine the presence and regional distribution of microglial activation, as assessed by \[F-18\]PBR06 PET, in subjects with MSA as compared to healthy controls, at baseline and at 9 months follow-up. Secondary: To assess the relationship between microglial activation and clinical progression at baseline and follow-up. Hypothesis: The working hypothesis is that there is microglial activation in Multiple System Atrophy and that the presence and regional distribution of microglial activation is different in MSA versus healthy controls and correlates with disease severity and comorbidities.
Interventions
- DRUG [F-18]PBR06
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2017-03-24 |
| Est. Completion | 2021-01-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03033680
The ClinicalTrials.gov registry entry for NCT03033680 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which [F-18]PBR06 is the first listed.
NCT03033680 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03033680 about?
NCT03033680 is a clinical study titled "Establishing 18F-PBR06 PET Imaging as a Viable Pharmacodynamic Endpoint in MSA". The specific aims of the study are: Primary: To determine the presence and regional distribution of microglial activation, as assessed by \[F-18\]PBR06 PET, in subjects with MSA as compared to healthy controls, at baseline and at 9 months follow-up. Secondary: To assess the relationship between m...
What is the current status of trial NCT03033680?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2017-03-24. Estimated completion is 2021-01-15.
What interventions are being tested in trial NCT03033680?
The interventions under investigation include: [F-18]PBR06 (DRUG).
Who is sponsoring clinical trial NCT03033680?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.